VTYX Insider Trading Activity and SEC Form 4 Filings
VTYX insider trading summary
Over the past 12 months, insiders at Ventyx Biosciences, Inc. (VTYX) reported 2 sales worth $463K by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $463K.
Latest VTYX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 18, 2025 | John Nuss | Chief Scientific Officer | Sell | $98K (12,675 @ $7.72) |
| Dec 18, 2025 | Raju Mohan | CEO and President | Sell | $365K (47,345 @ $7.72) |
| Apr 2, 2025 | John Nuss | Chief Scientific Officer | Sell | $2K (1,887 @ $1.07) |
| Dec 27, 2024 | John Nuss | Chief Scientific Officer | Sell | $50K (21,119 @ $2.36) |
| Dec 23, 2024 | Sheila Gujrathi | Insider | Buy | $301K (130,000 @ $2.31) |
| Dec 19, 2024 | John Nuss | Chief Scientific Officer | Sell | $30K (13,161 @ $2.26) |
| Nov 25, 2024 | Raju Mohan | CEO and President | Buy | $525K (261,752 @ $2.01) |
| Nov 22, 2024 | Raju Mohan | CEO and President | Buy | $435K (238,248 @ $1.83) |
| Apr 2, 2024 | Martin Auster | Chief Financial Officer | Sell | $8K (1,405 @ $5.40) |
| Apr 2, 2024 | Christopher W Krueger | Chief Business Officer | Sell | $9K (1,651 @ $5.40) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.